AEON

AEON Biopharma, Inc. [AEON] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

AEON Stock Summary

In the News

AEON Financial details

Company Rating
-
Market Cap
289.71M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
05 Jul 2024
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-7.35
Quick Ratio
0.12
Current Ratio
0.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
4.11%
SMA50
-1.3%
SMA100
85.37%
Inst Own
-
Inst Trans
-
ROA
-488%
ROE
20%
ROC
0.67%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.37-17.17
52W High
-95.41%
52W Low
-74%
RSI
53.7
Rel Volume
2.93
Avg Volume
58.37K
Volume
171.04K
Perf Week
-3.7%
Perf Month
7.29%
Perf Quarter
16.42%
Perf Half Y
20.18%
-
-
-
-
Beta
0.412
-
-
Volatility
0.02%, 0.04%
Prev Close
0.78%
Price
0.78
Change
8.18%

Something similar

Top by Market Cap
BRK-B
GOOGL
DHR-PB
3V64.DE
JPM
Same Sector
0M3O.L
UCB.BR
APS.TO
2005.HK
3141.T
Same Price Range
0821.HK
SMPL.NS
DYAI
KLAR.ST
EFF.DE
Similar Market Cap
DYNS
JHSC
GOODN
HAZ.TO
MBCN

Company Profile

Healthcare Biotechnology
  • Volume Average 58.37K
  • Market Capitalization 289.71M
  • Employee 10
  • CEO Mr. Marc Forth
  • Headquarters Newport Beach,CA,US
  • IPO Date 2023-07-24
  • Website http://www.aeonbiopharma.com

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.